The Phase III TAILORx clinical trial results indicate that most women with a specific early-stage breast cancer and midrange score on a gene expression assay do not need chemotherapy after surgery.
Roche has announced results from its Phase III IMpower130 trial. The findings demonstrate that Tecentriq® plus chemotherapy helped individuals with metastatic non-squamous NSCLC, who lived significantly longer compared with those who received chemotherapy alone
The FDA halted a Phase I/II trial that uses AstraZeneca’s Imfinzi (durvalumab) following the death of a patient.
Discover details of Bristol-Myer Squibbs latest immuno-oncology drug deal, DiaCarta’s funding into its diagnostic platform and Cancer Research UK’s pledge to invest £45 million into clinical trials.
Discover the biggest stories of 2018 ASCO-SITC in our conference news round-up.
Results of a Phase I study have suggested multisite stereotactic body radiotherapy prior to immunotherapy treatment may improve patient outcomes.
A phase III trial examining the use of cabozantinib for patients with previously treated advanced hepatocellular carcinoma has met its primary endpoint of overall survival.
In this interview discover further details of the JAVELIN Merkel 200 that led to the approval of the first immunotherapy treatment indicated in the EU and the first US FDA-approved systemic therapy for merkel cell carcinoma.
Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center (NC, USA) are developing a potential new immunotherapy strategy for melanoma.
A novel ‘labyrinth’ chip is isolating cancer cells from the blood of patients with an aggressive form of breast cancer in a clinical trial.
